465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)
Year: 2014
Type: article
Source: European Journal of Cancer
Authors: A. Kapoun, E. O'Reilly, A. Cohn, J.C. Bendell, L. Smith, J.H. Strickler, W. Gluck, Y.W. Liu, B. Wallace, R. Tam, B. Cancilla, A. Brunner, D. Hill, L. Zhou, J. Dupont, C. Zhang, M. Wang
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2004914144